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INTRODUCTION 
                          The immune compromised host is defined as a person who has 
an alteration in phagocytes, the humoral or cellular immunity that increases the 
risk of infectious complication 1. There is a growing group of individuals apart 
from ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) who are now 
immune suppressed like, those receiving immune suppressants for Solid Organ 
Transplants (SOT), Bone Marrow Transplant (BMT), Connective Tissue 
Diseases or treated with chemotherapeutic agents for cancer. Widespread use of 
“Biological Agents”, which are generally antibodies targeting specific cell type 
or pathway of inflammation, has further expanded the susceptible population. 
 Managing systemic infections are challenging in such patients among which 
pulmonary infection is very frequent. The development of pulmonary disease 
among such patients is considered as a serious problem. The differential 
diagnosis includes infectious and many non-infectious causes. Given the broad 
spectrum of potential infections and non-infectious causes, coupled with inherent 
toxicities of many therapies, a specific microbiological and cytopathological 
diagnosis should be considered essential to the management of pulmonary 
infections in non-HIV immune compromised host 2 
Noninvasive test available can be done easily with less risk, but overall they are 
of little diagnostic use and their yield is also low. So invasive strategies become 
essential for management of pulmonary diseases. Among the invasive test 
Bronchoscopy and Bronchoalveolar Lavage (BAL) has proved to be the 
procedure with good yield and is well tolerated even in critically ill patients, with  
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a low complication rate. It also leads to the most appropriate diagnosis. The 
sensitivity and specificity for diagnosing pulmonary infections is also good. 
Early diagnosis and appropriate treatment reduces the mortality and increases 
survival benefits. Hence, early bronchoscopy if possible before starting antibiotic 
therapy remains crucial in the management of immune compromised host with 
pulmonary infections.   
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REVIEW OF LITERATURE 
The immune compromised host is defined as a person who has an alteration in 
phagocytes, the humoral or cellular immunity that increases the risk of infectious 
complication or an opportunistic process like lymphoproliferative disease or 
cancer 1 
J.L.Mahon et al3., defines an immunocompromised patient is one with any defect 
in the immune system and immunodeficiency is applied to any person affected 
by disease or situations in which the immune system itself, including 
complement, phagocytes and lymphocytes is impaired  
CENTER FOR DISEASE CONTROL (CDC) 4 for practical purposes, 
divides immune compromising conditions into 3 broad categories 
A. Persons who are severely immune compromised not as a result of HIV 
infection; 
B. Persons with HIV infection; and 
C. Persons with conditions that cause limited immune deficits (e.g., asplenia, 
renal failure)  
SEVERELY IMMUNOCOMPROMISED, NON-HIV-INFECTED 
PERSONS 4 
1. Congenital immunodeficiency 
2. Leukemia, lymphoma, generalized malignancy 
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3. Therapy with alkylating agents, antimetabolites, radiation, or large 
amounts of corticosteroids 
MEDICAL CONDITIONS THAT CAUSE LIMITED IMMUNE 
DEFICIENCY 4 
1. Renal failure - End stage renal disease is associated with infections which 
contribute to 20% mortality, which is due to alteration in immune system5 
Matthias Girndt et al 6., in his article on the impaired cellular immune 
function in patients with end-stage renal failure states that patients with 
chronic renal failure are at increased risk of infections similar to other 
acquired immune defects. The secondary immune failure is due to uremic 
intoxication per se and by altered renal metabolism of immunologically 
active proteins. 
2. Alcoholic cirrhosis 
3. Asplenia 
The IDSA7 (INFECTIOUS DISEASE SOCIETY OF AMERICA) has defined 
immune suppression as High & Low level immune suppression. 
HIGHLEVEL IMMUNOSUPPRESSION INCLUDES: 
1. Combined primary immunodeficiency disorder (eg, severe combined 
immunodeficiency) 
2. Receiving cancer chemotherapy 
3. Within 2 months after solid organ transplantation 
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4. With HIV infection with a CD4 T-lymphocyte count <200 cells/mm3 for 
adults and adolescents and < 15% for infants and children 
5. Receiving daily corticosteroid therapy with a dose ≥20 mg (or >2 
mg/kg/day for patients who weigh <10 kg) of prednisone or equivalent for 
≥14 days 
6. Receiving certain biologic immune modulators, that is, a tumor necrosis 
factor-alpha (TNF-α) blocker or rituximab 
 LOW-LEVEL IMMUNOSUPPRESSION INCLUDES: 
1. Asymptomatic HIV-infected patients with CD4 T-lymphocyte counts of 
200–499 cells/mm3 for adults and adolescents and 15–24 % for infants 
and children 
2. Those receiving a lower daily dose of systemic corticosteroid than for 
high-level immune suppression for ≥14 days or receiving alternate-day 
corticosteroid therapy  
3. Those receiving methotrexate (MTX) ≤0.4 mg/kg/week, azathioprine ≤3 
mg/kg/day, or 6-mercaptopurine ≤1.5 mg/kg/ day 
ETIOLOGY AND DIFFERENTIAL DIAGNOSIS FOR PULMONARY 
DISEASES IN NON-HIV IMMUNE SUPPRESSED 
Includes both infectious & non-infectious etiologies.  
Rañó A et al 8., in his study of pulmonary diseases in non-HIV immuno 
compromised patients found that 77% of pulmonary diseases were infectious and 
remaining 23% were non-infectious and among non-infectious causes pulmonary 
edema and alveolar haemorrhage were most common. 
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Similarly, Rosenow EC, et al 9., observed the same differential diagnosis for 
pulmonary diseases among non-HIV immunocompromised host. In his study he 
observed 25% of pulmonary diseases were due to non-infectious causes. 
Bianca Harris et al 10., in his focussed review on Bronchoscopy in Solid Organ 
and Haematopoietic transplant patients observed the following differential 
diagnosis for pulmonary diseases. 
Table 1. Differential diagnosis of pulmonary disease in non-HIV immuno 
compromised host 10,11 
1. Infection                                                          7. Acute rejection 
2. Drug induced pulmonary disease                    8. Malignancy 
3. Recurrence of underlying disease                   9. Pulmonary edema. 
4. Pulmonary haemorrhage                                   10. Combination of above  
5. Idiopathic fibrosis 
6. ``Unrelated'' disease 
 
 
PULMONARY INFECTIONS IN NON-HIV IMMUNOCOMPROMISED 
Infections are the most common cause of pulmonary diseases. An unilateral, 
localized process is very likely to be infectious in origin (90%), whereas diffuse 
disease is somewhat less frequent (75%) 12,13,14 
Nimrod Maimon et al 11., approaches the differential diagnosis of pulmonary 
infections in two ways, first is to relate the various organisms to defect in primary 
immune system, the more important second one is to consider the probability of 
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various organisms in context of different underlying immune defect11. According 
to him the pathogens summarized below account for 90% of opportunistic 
infections. 11 
Table 2. The most common infectious organisms 11 
Bacteria Fungi Viruses Protozoa 
Staphylococcus 
Aureus 
Pneumocystis 
carini 
Cytomegalovirus Toxoplasma 
gondii 
Streptococcus 
pneumoniae 
Candida sp. Herpes simplex Strongyloides 
stercoralis 
Staph. epidermidis Aspergillus sp. Herpes zoster  
Pseudomonas 
aeruginosa 
Histoplasma 
capsulatum 
Respiratory 
syncytial virus 
 
Escherichia coli Blastomyces 
dermatitidis 
Influenza A  
Legionella Coccidioides immitis Enterovirus  
Nocardia Cryptosporidium 
neoformans 
  
Mycobacteria sp.    
 
Bacterial, fungal, viral, and mycobacterial pathogens may infect the lungs of 
immunosuppressed patients.  In a prospective series by Rano et al 8., among 200 
non-HIV immunocompromised patients, infectious agents were recovered from 
more than three fourth of subjects. An etiological diagnosis was obtained in 81% 
with 19% no diagnosis. Among the 81%, infections were 77% and non-infectious 
causes contributed to 23%. Among infections bacterial was predominant with 
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23%, followed by fungal with 17% and viral with10% 8. According to Andrew 
F. Shorr, MD et al.,15 the most common bacterial organisms are nosocomial 
organisms like Pseudomonas and MRSA. Aerobic Gram-negative bacilli such as 
Klebsiella pneumonia may also lead to pneumonia 
SPECTRUM OF PULMONARY FUNGAL INFECTIONS  
Aspergillus infection remains the most common cause of fungal pneumonia 15. 
Aspergillus species have emerged as important causes of morbidity and mortality 
in immunocompromised patients 16. Among the Aspergillus species, Aspergillus 
fumigatus is the most common species recovered 17.  
Paterson DL, et al.12 found Aspergillus infection occurs in 1 to 8% of patients 
undergoing various solid organ transplants (SOTs) and Hematopoietic stem cell 
transplants (HSCTS). Chest pain, dyspnea, and hemoptysis are the classical 
presenting symptoms. Some patients initially have no symptoms.  
Jantunen et al 13 in his series on invasive and probable fungal infections among 
bone marrow transplant recipients observed Aspergillus was the most frequent 
cause and only 50% had chest symptoms, 32% had fever and remaining were 
asymptomatic. The triad of symptoms of chest pain, hemoptysis, dyspnea can 
occur in pulmonary embolism leading on to confusion in diagnosis. The chest 
radiograph may initially be normal in upto 10% of cases.12 Hence, early use of 
CT scan is necessary 12. An area of low attenuation may arise next to areas of 
consolidation referred as halo sign. But it is not specific and is also a late 
finding12. Infections due to other angioinvasive filamentous fungi, such as 
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Zygomycetes, Fusarium species, and Scedosporium species, as well as to 
Pseudomonas aeruginosa and Nocardia species, may cause a halo sign.16  
 Calliot D, et al 14., in his study of definitive Aspergillus cases, the sensitivity of 
halo sign was only 50%. The yield of bronchoscopy for aspergillosis in immune 
suppressed patients is approximately 50% 
 FREDERICK W. KAHN et al 18., in his study of 82 immunocompromised 
patients undergoing bronchoscopy for pulmonary infiltrates found that 
Aspergillus hyphae was found 9 out 17 cases with invasive aspergillosis. BAL 
had a sensitivity of 53% and specificity of 97% and positive predictive value of 
75% as per his study. Thus he concluded that BAL was a valuable procedure for 
diagnosing invasive aspergillosis. The newer techniques like galactomannan 
assay has sensitivity 80-90% and specificity > 95%.19,20.   
The other important fungi that cause pneumonia in immunocompromised 
patients are endemic mycosis Histoplasma capsulatum, Coccidioides immitus, 
and Blastomyces dermatitidis 15.  
Candida though often isolated from respiratory tract of immunocompromised 
patients rarely cause pneumonia except in lung transplant recipients 15. Haron E 
et al 21., in his study identified primary candida pneumonia in only 0.4% of 
autopsies at the M.D. Anderson Cancer Center. Since the isolation of Candida 
often represents colonization rather than true infection attributing pulmonary 
infiltrates to Candida pneumonia is difficult. Demonstration of tissue invasion by 
transbronchial or surgical lung biopsy is required for definitive diagnosis. But 
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even though Candida is frequently a colonizer, Respiratory tract Candida 
colonization is associated with worse clinical outcomes and is independently 
associated with increased hospital mortality 22,23. 
PNEUMOCYSTIS CARINII PNEUMONIA  
Yale SH, et al 24., found in his study up to 90% of Pneumocystis carinii 
pneumonia occur in patients treated with steroids within 4 weeks of diagnosis. 
He found the mean corticosteroid dose was 30mg/day and mean duration of 
steroid therapy was 12 weeks before the development of pneumonia. 
Pneumocystis carinii pneumonia also has been linked directly to Fludarabine 
therapy for CLL 25. The radiological pattern tends to be bilateral with fine 
Perihilar or small nodular infiltrates.  
BAL has a very good yield for PCP. The BAL yield for PCP with conventional 
stain is 80% in non-HIV & 95% in HIV patients 26 
PREVALENCE OF PULMONARY TUBERCULOSIS  
The incidence of tuberculosis varies depending on the underlying cause for 
immunosuppression. In areas where Tuberculosis is highly prevalent the 
possibility of tuberculosis is high.  
Jane C. Chan et al.27, in his study in Hong Kong among 62 Non-HIV 
immunocompromised found that tuberculosis was the second most common 
cause of pulmonary infections after bacterial infections. The incidence of 
tuberculosis was 19%. The overall bronchoscopic sensitivity for tuberculosis 
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was 91%. The radiographic presentation was nonspecific. Hence in countries 
where there is high prevalence of tuberculosis, bronchoscopy should be utilized 
readily for smear negative cases in immunocompromised patients and empirical 
treatment may be started awaiting culture results 27 
NON-INFECTIOUS ETIOLOGIES 
There are various non-infectious causes of pulmonary diseases in 
immunocompromised. Upto 25% of pulmonary diseases in 
immunocompromised can be attributed to non-infectious causes 8,28. Some of the 
non-infectious causes can have a poorer prognosis. 
PULMONARY EDEMA 
Pulmonary edema is one of the common non-infectious causes of pulmonary 
disease.  Andrew F. Shorr et al15., states that the 
Causes of pulmonary edema include, 
1. Hydration prior to chemotherapy for leukemia. 
2. Volume overload status in chronic kidney disease patients and sometimes 
post renal transplant patients. 
3. Chemotherapeutic agents like doxorubicin induced cardiotoxicity. 
4. Indirect causes like drugs, radiation, sepsis, that promotes lung injury and 
capillary leak. 
Patients have diffuse pulmonary infiltrates predominantly involving lower lobes 
and are afebrile. Some patients can even decompensate quickly, but respond to 
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treatment well and the prognosis is good. Hence extreme care needs to be taken 
while assessing the fluid status of immunocompromised patients. 15 
RECURRENCE OF UNDERLYING DISEASE 15 
In patients with underlying malignancy the disease progression may result in the 
development of pulmonary disease. The infiltrates may be discrete nodules, 
masses, diffuse alveolar infiltration as seen in lymphomas or lymphangitic 
pattern with interstitial involvement may also occur. Bronchoscopy helps to rule 
out infections and helps to get the tissue biopsy needed to prove the diagnosis. 
DRUG INDUCED PULMONARY DISEASE 15 
Many drugs are associated with pulmonary toxicity. Some like Busulfan are 
directly implicated in causing pulmonary disease. Pathological patterns of drug 
induced lung disease may be in the form of diffuse alveolar damage (DAD), 
granulomatous reactions, and nonspecific pneumonitis 28. The diagnosis of drug 
induced lung damage is made clinically,  
1. The temporal relationship between the use of a particular agent and the 
subsequent development of symptoms 
2. Improvement in pulmonary function after withdrawal of the agent  
3. Exclusion of infection 
Some common drugs associated with pulmonary toxicity include Busulfan, 
Cyclophosphamide, Methotrexate, Azathioprine, Bleomycin etc... 15,28 
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RADIATION INDUCED LUNG INFILTRATES  2 
Radiotherapy for malignancies can involve the lungs. They result in acute 
pneumonitis or more slowly, progressive pulmonary fibrosis. Following a dose 
of radiation to the lungs >2000 rads, radiation injury may be seen. The acute form 
of radiation pneumonitis may present as bronchitis or esophagitis, with dry 
cough, fever, fatigue, hypoxemia, and dyspnea that develop over 6 to 12 weeks. 
Radiation fibrosis usually occur in 6 to 9 months, and pulmonary function may 
take upto 2 years to plateau. Radiation injury may follow a unique pattern on CT 
chest. The lesions are sharply defined and bounded. They do not follow the 
anatomic border.   
DIFFUSE ALVEOLAR HAEMORRHAGE 
Diagnosed by bloodier return from BAL and the presence of hemosiderin laden 
macrophages. If 20% of the alveolar macrophages are hemosiderin laden, then 
DAH is present 29. Radiography shows diffuse alveolar infiltrates in middle and 
lower lung fields. The incidence ranges from 2 to 14% 29. The pathogenesis of 
DAH is unclear. DAH likely arises following an initial lung injury from either 
chemotherapy or irradiation that results in endothelial damage 29,30. Treatment 
consists of high-dose corticosteroids. Dosages used have ranged from 500 mg to 
2 g per day of IV Methylprednisolone 29,30 
MORBIDITY AND MORTALITY OF PULMONARY INFECTIONS 
Pulmonary complications remain one of the most common causes of morbidity 
and mortality.  Nimrod Maimon MD, et al 11., in his review article states that the 
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lungs are involved in at least 75% of immunocompromised patients with any 
complication. Mortality rate ranges widely from 15%-90%, depending on the 
underlying disease, the severity of lung involvement, and the total impairment of 
host defenses. 11   The development of pulmonary disease in immunosuppressed 
patients is a diagnostic challenge 11 
Poe RH et al 31., in his study on Predictors of mortality in the 
immunocompromised patient with pulmonary infiltrates found a mortality rate of 
36%.   Rañó A et al32., in his study on 200 non-HIV immunocompromised 
patients found an overall mortality rate of 39%. 
These studies show the need for rapid and quick evaluation of pulmonary disease 
in immunocompromised patients to prevent mortality.  
ROLE OF FOB IN DIAGNOSTIC EVALUATION OF PULMONARY 
INFECTIONS IN NON-HIV IMMUNOCOMPROMISED HOST 
Pulmonary diseases in non-HIV immunocompromised patient have a variety of 
differential diagnosis. Apart from infections different non-infectious causes are 
also predominant 
A Rano et al 8., in his study on 200 non-HIV immunocompromised patients 
observed that, in infectious causes when appropriate treatment was changed 
earlier < 7 days had a better outcome (29% mortality) than treatment changed 
later (71% mortality). This study highlights the importance that the quick 
evaluation and treatment modification reduces the mortality 
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A Similar finding was also observed by DANÉS et al.,33 in immunocompromised 
patients where bacterial pneumonia was most common followed by fungal and 
viral pneumonias. In his study bacterial pneumonia was associated with unilateral 
and alveolar type of infiltrates. BAL had a diagnostic yield of 52%. Staph aureus 
was the most common bacterial pathogen and Aspergillus was most common 
fungal isolates.  
FREDERICK W. Kahn et al.,34 in his study on 94 immunocompromised patients 
where 100 BAL procedure was done found bronchoscopic yield of 81% for 
infections. The non-infectious causes observed were malignancy, haemorrhage, 
pulmonary edema, radiation fibrosis etc. The yield with BAL was similar to that 
of Trans Bronchial biopsy. 
S SHAWGI et al 35., in a study done on 25 patients with hematological 
malignancies in INDIA found that overall yield was high with 84%. Bacterial 
pneumonia alone accounted for 40% and 40% polymicrobial, fungal alone 
remaining 4%. Pseudomonas was most common bacteria and Aspergillus 
fumigatus was most common fungi isolated. The therapeutic utility was 24%. 
PITFALLLS OF EMPERICAL TREATMENT 
More often clinicians treat patients empirically. The mortality may be high if 
empirical treatment is not modified early once the patient does not improve 8.  It 
is not possible to cover all diagnostic aetiologies by empirical treatment. 
Moreover, empiric treatment purely based on clinical criteria alone would be 
unacceptable given the toxicity associated with such treatment options in most 
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circumstances. Many of the non-infectious aetiologies are unnecessarily treated 
with antimicrobials contributing to drug resistance and toxicity. Also, most non-
infectious causes are also potentially fatal if not diagnosed and treated correctly. 
Finally, many non-infectious conditions like DAH may require corticosteroids 
for their management, which may exacerbate the underlying pulmonary 
infections if not ruled out properly. Hence ruling out infections thoroughly is 
mandatory before starting corticosteroid therapy for management of non-
infectious causes and also for continuing immunosuppresive therapy 11. 
Infections in immunocompromised hosts often present without the expected 
signs and symptoms of infection. Many non-infectious cause like DAH, radiation 
pneumonitis, malignancy may also present with fever mimicking infections. 
Hence clinicians must follow an aggressive approach and must have a low 
threshold for performing investigations when encountered with an 
immunocompromised patient with pulmonary diseases. Invasive studies such as 
bronchoscopy or biopsy are best performed early in the course of possible 
infection and prior to the initiation of antimicrobial therapy 36. 
DRAWBACKS OF NON-INVASIVE TECHNIQUES 
The non-invasive diagnostic methods include serologic tests, blood antigen 
detection, nasopharyngeal wash, sputum, and tracheobronchial aspirate cultures, 
chest radiograph, CT chest, sputum AFB staining, Grams staining, Skin tests etc. 
Though blood cultures are done routinely, they have a low diagnostic yield. 
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A Rano et al 8., in his study found that yield of blood culture was only 16% & 
sputum culture with 30%. Bronchoscopic yield was 59%. Thus he concluded that 
BAL had a higher diagnostic yield and impact on therapeutic decisions. Also 
Sputum culture is valuable only when the organisms not routinely found in 
oropharyngeal secretions are isolated like mycobacteria, Mycoplasma etc 11. 
Danes et al 33., in his study found that non-invasive technique like sputum culture 
was associated with low yield of only 20%, blood culture with 8%, and 
nasopharyngeal wash for viral antigen detection was only 6%, compared to 
bronchoscopic yield of around 66%. 
Though standard chest radiograph can be used as a screening tool in 
immunocompromised patients with chest symptoms, studies have advocated 
early use of CT scans. A study in renal transplant recipients showed that though 
chest radiograph was initially normal in patients with pulmonary complaints 
subsequent CT scan demonstrated abnormalities 37. Heussel et al 38., in a study on 
87 patients with febrile neutropenia found that in 50% patients CT revealed 
lesions that were not visualized by chest radiography. Thin section CT was able 
to detect pneumonia 5 days earlier compared to chest radiograph. CT in addition 
to identifying lesion missed on chest radiography helps to guide invasive 
diagnostic procedures like BAL, TBLB etc. 
Even though the non-invasive diagnostic techniques are safe and relatively low 
cost studies have shown that they add little useful information 8,11,39. The overall 
diagnostic yield of non-invasive techniques ranges from 10%-30% 8,33. 
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Hence, due to varied aetiology of pulmonary diseases along with non-specific 
nature of clinical and radiological presentation coupled with low yields of non-
invasive techniques makes invasive diagnostic procedures mandatory. The 
benefit to risk ratio is an important consideration when choosing an invasive 
procedure in immunocompromised patients who are already critically ill due to 
the underlying disease. The invasive procedure with good yield and low risk in 
most of the studies is BAL.11,40,41 Lavage is safe, minimally invasive, 
reproducible and leads to a quick diagnosis. Suitable even for very sick and 
critically ill patients with less complications. The yield of BAL is better than of 
Protected brush Sampling, although PBS is more specific.42,43 
Jennifer A Crockett, MD et al 42., in his study found that yield of BAL was 38% 
compared to PBS with 10% and TBB with 27%. Adding BAL, PBS, 
Transbronchial biopsy during the bronchoscopic procedure increases the 
diagnostic yield, sensitivity and specificity at the same time complication rate of 
the procedure 43. 
 Rano et al 8, in his study found that BAL had the best diagnostic yield of 51%, 
better than PBS (24%), with only 3 minor complications and led to treatment 
modification in 38%. 
Gruson D et al 44., studied the role of bronchoscopy in the management of 
pulmonary infiltrates in neutropenic patients found that BAL had a complication 
rate of 17% and acceptable yield of 49% 
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AIMS AND OBJECTIVES 
PRIMARY OBJECTICTIVES 
 To study the 
DIAGNOSTIC YIELD OF BRONCHOSCOPY 
MODIFICATION OF CURRENT EMPIRICAL TREATMENT AS THE 
RESULT OF BRONCHOSCOPIC INTERVENTION. 
among NON-HIV immunocompromised patients presenting with pulmonary 
diseases in a tertiary care center. 
SECONDARY OBJECTIVES: 
 To collect data on etiology of different microorganisms among Non-
HIV immunocompromised patients. 
 To collect data on non-infectious causes of pulmonary diseases in 
Non-HIV immunocompromised patients in our tertiary care center. 
 Compare symptoms at the time of presentation, with bronchoscopic 
yield. 
 Compare the different radiological pattern, with bronchoscopic yield. 
 Compare different subgroups of Non-HIV immunocompromised 
patients with regards to presenting symptoms, radiological patterns, 
bronchoscopic yield, treatment modification, different spectrum of 
infections & complications.  
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MATERIALS & METHODS  
STUDY CENTER 
The study was conducted in Rajiv Gandhi Government General Hospital, Park 
Town, Chennai, which is a tertiary care institute. 
STUDY DESIGN: 
 The study was a prospective observational study. 
 Consecutive immunocompromised patients who presented with 
pulmonary diseases were included in the study. 
 No specific method of randomization was used. 
 No controls were used in the study. 
STUDY PERIOD: 
8 months, from January 2016 – August 2016. 
SUBJECT SELECTION: 
A total 592 patients referred from other departments like Oncology, Nephrology, 
Rheumatology, Hematology from January 2016 – July 2016 above the age of 12 
years to Thoracic medicine department for evaluation of pulmonary diseases 
were screened. 
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INCLUSION CRITERIA: 
Among them 120 patients satisfying definition of immunosuppression with any 
one of the following features were evaluated, 
1. Chest symptoms like cough, sputum, breathlessness, chestpain, 
hemoptysis with or without fever. 
2. Abnormal auscultatory finding like crackles, wheeze with or without 
symptoms. 
3. Presence of pulmonary infiltrates in radiography 
Immunosuppression was defined by standard guidelines using IDSA 9 and     
CDC 4 guidelines on vaccination for immune compromised host. 
DEFINITION FOR IMMUNOSUPPRESSION 
1. Receiving cancer chemotherapy 
2. Receiving daily corticosteroid therapy with a dose ≥20 mg of prednisone 
or equivalent for ≥14 days 
3. Receiving certain biologic immune modulators, that is, tumor necrosis 
factor-alpha (TNF-α) blocker or rituximab 
4. Those receiving methotrexate (MTX) ≤0. 4 mg/kg/week, azathioprine ≤3 
mg/kg/day, or 6-mercaptopurine ≤1. 5 mg/kg/day 
5. Solid organ transplant recipients 
6. Hematological malignancies 
7. Chronic kidney disease on hemodialysis 
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EXCLUSION CRITERIA: 
Out of the 120 patients satisfying inclusion criteria 30 patients were excluded 
from the study based on the following reasons, 
1. All HIV positive patients were excluded from the study. 
2. All sputum AFB smear positive pulmonary tuberculosis were excluded 
from the study. 
3. Patients having very poor general condition, very severe breathlessness, 
recent history of myocardial infarction and patients not fit for 
bronchoscopy. 
4. Patients not willing to give informed written consent. 
METHODOLOGY 
 Bronchoscopy was planned in the remaining 90 patients and they underwent 
complete clinical evaluation. 
Informed consent was obtained after explaining the nature of the study. 
1. The following data were collected from the patient  
• Name, Age, Sex, Residential address, Occupation 
2. Detailed clinical history was collected which included 
• The presenting complaints/symptoms and their duration, including 
presenting illness. 
• The nature of the primary disease for which patients are undergoing 
current treatment like, Chronic Kidney Disease, Rheumatological 
Diseases, Carcinoma, Hematological diseases etc. 
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• The past history of any similar illness or respiratory problems 
• A detailed treatment history, which includes the immunosuppressive 
agents patients are currently receiving like corticosteroids, Biological 
Agents, chemotherapeutic agents etc., their dosage and duration. 
• Personal history, family history and occupational history 
• History of any comorbidities such as coronary artery disease, recent MI, 
systemic hypertension, Diabetes Mellitus etc. 
3. General examination and a structured clinical examination of the respiratory 
system and other systems were done. 
4.  Basic blood investigations were done in all patients like Complete blood 
count, Renal function test, Bleeding time, Clotting time, Prothrombin time, 
Activated partial thromboplastin time.  
5. Chest Skiagram anteroposterior, lateral view, routinely Plain computed 
tomography (CT CHEST) chest/contrast enhanced computed tomography 
chest (CECT-CHEST)/ High resolution computed tomography chest (HRCT-
CHEST) were done as required depending on the patient's diagnosis and 
clinical status. 
6.  A careful pre-evaluation and cardiac fitness which includes an echo was done 
prior to Fiber optic bronchoscopy (FOB) in all patients. 
 After complete clinical evaluation, blood investigations and pre procedure 
evaluation ,10 patients were excluded from the study for following reasons 
• Very high cardiac risk  
• Coagulation abnormalities or very low platelet count < 50,000 cells/mm3 
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 The remaining 80 patients included in study were already receiving empirical 
antimicrobial therapy for their abnormal symptoms, signs or radiological 
lesions by the treating physician. Out of which 11 patients who showed 
clinical improvement to the current empirical treatment as noted by the 
treating physician during pre-procedure evaluation were further excluded 
from the study. 
 The remaining 69 underwent bronchoscope. Bronchoscopy (FOB) was done 
as per British Thoracic Society guideline for diagnostic flexible 
bronchoscopy in adults using an Olympus fiber optic bronchoscope and strict 
disinfection protocol was followed for disinfecting the scope pre and post 
bronchoscopy as per the above mentioned guidelines 45 
 In 4 patients bronchoscopy could not be completed due to poor patient 
cooperation were further excluded from the study 
SAMPLE SIZE 
A total 65 patients FOB was completed and BAL sample was sent for analysis 
ANALYSIS OF BAL SAMPLE 
Bronchoalveolar lavage was done from the lobe affected and segment involved 
and sample collected was sent for  
 GENE XPERT MTB 46 – A real time cartridge based nucleic acid 
amplification test for diagnosis of Mycobacterium Tuberculosis done 
at STATE INTERMEDIATE LEVEL REFERENCE 
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LABORATORY AND INSTITUTE OF THORACIC MEDICINE, 
CHETPET. 
 AFB staining 
 Bacterial culture and sensitivity & Grams staining 
 Fungal culture & KOH staining 
 Cytology 
During bronchoscopy  
 Transbronchial & Endobronchial biopsy was done as required on case 
to case basis provided there were no contraindications to procedure 
like, prolonged bleeding time, clotting time, severe hypoxemia likely 
to worsen during bronchoscopy, Poor general condition, unstable 
cardiovascular status, advanced renal failure etc 47,48. 
TECHNIQUE OF BRONCHOALVEOLAR LAVAGE 49 
 Bronchoalveolar Lavage was done as per the standard guidelines 
prescribed by European Respiratory Task Force – Recommendation of 
standardized of BAL Technique (1999) 49 
PROCESSING OF BRONCHO ALVEOLAR LAVAGE SAMPLE 
The BAL sample obtained was collected in a sterile container (sterile uricol). 
They were then transported as early as possible to the lab in sample carrier with 
ice packs. If any delay in transport they were stored immediately in the 
refrigerator at (2-8˚C). 
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SAMPLE PROCESSING  50 
The samples were immediately processed after reaching the lab using standard 
microbiological techniques. Routine methods like Gram’s staining and AFB 
(Acid Fast Bacilli) staining were done on all samples. Then they were inoculated 
on standard culture media for detecting bacterial growth like blood agar and Mac 
Conkey agar (MAC). Culture for fungi was done by using Sabouraud’s Dextrose 
Agar (SDA) medium. To check the presence of fastidious organisms and also to 
rule out the presence of anaerobic organisms special media like Thioglycollate 
broth (TGB) was also inoculated. 
The plates and tubes were incubated at 37C in an incubator. The blood agar plates 
were incubated in a candle jar with 5-10% Co2.  After overnight incubation, the 
plates and tubes were examined for presence of growth. The TGB tubes were 
incubated till 7 days before declaring a negative result. The SDA plates were 
incubated for 4 weeks to allow for the growth of slow growing fungi. 
If growth was present in Blood agar (BA) and MAC plates, then the significance 
of the growth was assessed by doing a colony count. In a BA plate the hemolysis 
produced by the colonies are noted. Standardized tests like catalase and oxidase 
tests were performed on colonies from non-selective medium.  
Identification of the bacterial species is done by using standard biochemical tests 
like an Indole test (using Kovac’s reagent), MMM medium (Mannitol Motility 
Medium), citrate test, urease test, Triple Sugar Iron medium (TSI) and sugar 
fermentation tests. 
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Identification of the fungal species is done by detecting growth in SDA plates 
and doing an LPCB (Lacto Phenol Cotton Blue) mount on the culture. Yeasts 
like Candida were identified using Gram’s staining, germ tube test and 
assimilation and fermentation tests. Speciation of Candida was done using a 
special media called CHROM agar. 
DIAGNOSTIC CRITERIA TO DETERMINE INFECTIOUS ETIOLOGY 
IN BAL 
1. TUBERCULOSIS: AFB staining positive in lavage fluid or MTB detected 
by CBNAAT (Real Time Cartridge Based Nucleic Acid Amplification 
Method) 
2. BACERIAL INFECTIONS: BAL fluid contains >=104 CFU/ml in cultures 
of BAL 1 ml and < 1% squamous epithelial cells in Geimsa stained smears51,34 
3. FUNGAL INFECTIONS: (European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Cooperative Group 
DEFINITION WAS USED) 
 Revised Definitions of Invasive Fungal Disease from the European 
Organization for Research and Treatment of Cancer/Invasive Fungal 
Infections Cooperative Group and the National Institute of Allergy and 
Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus 
Group52 
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 Criteria for proven invasive fungal disease except for endemic 
Mycoses 
 Microbiological analysis:  
Histopathologic, cytological or direct microscopic examination of a 
specimen obtained by needle aspiration or biopsy in which hyphae or 
melanized yeast-like forms are seen accompanied by evidence of 
associated tissue damage 
 Culture 
Recovery of a mold or “black yeast” by culture of a specimen obtained by 
a sterile procedure from a normally sterile and clinically or radiologically 
abnormal site consistent with an infectious disease process, excluding 
bronchoalveolar lavage fluid, a cranial sinus cavity specimen, and urine 
• Criteria for probable invasive fungal disease except for Endemic 
Mycoses 
1. Host factors: 
a. Recent history of neutropenia (<500 neutrophils/mm3 for >10 
days) temporally related to the onset of fungal disease  
b.  Receipt of an allogeneic stem cell transplant  
c.  Prolonged use of corticosteroids (excluding among patients with 
allergic bronchopulmonary aspergillosis) at a mean minimum dose 
of 0.3 mg/kg/day of prednisone equivalent for >3 weeks  
d.  Treatment with other recognized T cell immunosuppressants, 
such as cyclosporine, TNF-α blockers, specific monoclonal 
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antibodies (such as alemtuzumab), or nucleoside analogues during 
the past 90 days  
e.  Inherited severe immunodeficiency (such as chronic 
granulomatous disease or severe combined immunodeficiency) 
2. Clinical criteria: Lower respiratory tract fungal disease 
 The presence of 1 of the following 3 signs on CT: 
a. Dense, well-circumscribed lesions(s) with or without a halo sign 
b. Air-crescent sign 
c. Cavity 
3. Mycological criteria: 
A. DIRECT TEST (cytology, direct microscopy, or culture) 
 Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate 
samples, indicated by 1 of the following: 
• Presence of fungal elements indicating a mold 
• Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or 
Scedosporium species) 
            B. INDIRECT TESTS (detection of antigen or cell-wall constituents) 
Aspergillosis 
• Galactomannan antigen detected in plasma, serum, BAL fluid, or CSF 
• Invasive fungal disease other than cryptococcosis and zygomycoses 
• β-d-glucan detected in serum 
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CRITERIA FOR THE DIAGNOSIS OF ENDEMIC MYCOSES 
(Endemic Mycoses includes histoplasmosis, blastomycosis, coccidioidomycosis, 
paracoccidioidomycosis, sporotrichosis, and infection due to Penicillium 
marneffei.) 
PROVEN ENDEMIC MYCOSIS 
In a host with an illness consistent with an endemic mycosis, 1 of the following:  
a. Recovery in culture from a specimen obtained from the affected site or 
from blood  
b. Histopathologic or direct microscopic demonstration of appropriate 
morphological forms with a truly distinctive appearance characteristic of 
dimorphic fungi, such as Coccidioides species spherules, Blastomyces 
dermatitidis thick-walled broad-based budding yeasts, Paracoccidioides 
brasiliensis multiple budding yeast cells, and, in the case of 
histoplasmosis, the presence of characteristic intracellular yeast forms in 
a phagocyte in a peripheral blood smear or in tissue macrophages 
PROBABLE ENDEMIC MYCOSIS 
 The presence of a host factor, including but not limited to those specified plus a 
clinical picture consistent with endemic mycosis and Mycological evidence, such 
as a positive Histoplasma antigen test result from urine, blood, or CSF 
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TREATMENT MODIFICATION & FOLLOW UP  
• Patients were allowed to continue with same empirical treatment until the 
results of bronchoscopy were available. 
• Appropriate Treatment modification was done based on the results. 
• Patients diagnosed as tuberculosis were started on Anti-Tuberculous 
Treatment. 
• For bacterial infections antimicrobials were changed as per culture 
sensitivity pattern if needed. 
• For fungal infections antifungals were started in patients with proven 
and probable invasive fungal infections. 
• Patients diagnosed with malignancy and lymphoma were referred back 
to oncology department for restarting chemotherapeutic regimens. 
Patients were followed up until the signs of clinical improvement or discharge or 
death in hospital. Post discharge patients were enquired for clinical improvement 
during their follow up visits to the hospital or through telephone calls. 
DEFINITIONS 
INFECTIOUS ETIOLOGY 
When microorganisms grown in culture consistent with above diagnostic criteria 
for bacterial or fungal infections or BAL fluid AFB smear positive or MTB 
detected in GeneXpert. 
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NON-INFECTIOUS ETIOLOGY 
No organism isolated from a bacterial/fungal culture or AFB staining negative or 
GeneXpert MTB not detected. 
PLUS 
Alternative diagnosis established by cytology positive for malignant cells or HPE 
proof for lymphomatous infiltration or malignancy or radiation fibrosis or DAH 
was diagnosed by established criteria 53,54 
POSITIVE YEILD OF FOB:  
When an infectious or non-infectious cause was established by bronchoscopy. 
NEGATIVE / NON-DIAGNOSTIC YEILD: 
When no definitive infectious or non-infectious cause could be established by 
bronchoscopy.  
STATISTICAL ANALYSIS: 
All statistical analysis was performed using the Statistical Package for Social 
Science (SPSS, version 17) for Microsoft windows. Descriptive statistics were 
presented as numbers and percentages A chi-square test was used for comparison 
between two attributes. A two-sided p value < 0.05 was considered statistically 
significant. 
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STUDY PROTOCOL 
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RESULTS AND ANALYSIS 
AGE DISTRIBUTION: 
A total number of 65 patients were included in the study. 
 The mean age of 65 patients was 41.91 with a standard deviation of 15.5. The 
age of patients ranged from 15 years – 74 years. The patients were equally 
divided among two age groups < 40 years & > 40 years with 51% and 49% 
respectively. 
TABLE 3: AGE DISTRIBUTION 
AGE DISTRIBUTION 41.91 +/- 15.5 
 Freq Percentage 
< 40 YEARS 33 51% 
> 40 YEARS 32 49% 
TOTAL 65 100 
  
 
51% (33)49% (32)
AGE DISTRIBUTION
N=65
< 40 YEARS
> 40 YEARS
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FIG 1: AGE DISTRIBUTION 
GENDER DISTRIBUTION: 
Out of 65 patients included in study 36 were male and 29 were females. Thus, 
ratio was 55% & 45% male to female.  
TABLE 4: GENDER DISTRIBUTION 
 
 
 
FIG 2: GENDER DISTRIBUTION 
 
GENDER DISTRIBUTION 
N=65
GENDER DISTRIBUTION 
 FREQ % 
MALE 36 55% 
FEMALE  29 45% 
TOTAL 65 100% 
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DIFFERENT GROUP OF IMMUNOCOMPROMISED PATIENTS 
INCLUDED IN THE STUDY 
The 65 patients included in the study were divided into 5 groups based on their 
disease pattern and nature of immunosuppresion 
GROUP 1: Cancer patients who were receiving chemotherapy in past 6 months 
GROUP 2: Post Renal Transplant recipients who were receiving 
immunosuppresants. 
GROUP 3: Chronic Renal Failure patients currently receiving haemodialysis 
GROUP 4: Patients with Hematological Malignancies who were 
immunosuppressed because of their disease per se as well as receiving 
chemotherapy 
GROUP 5: Connective Tissue Disease patients like SLE, RA, etc, who were 
receiving steroids > 20 mg/day for more than 1 month or receiving 
immunosuppressive drugs or Biological agents. 
TABLE 5: DIFFERENT GROUPS OF IMMUNOCOMPROMISED PATIENTS 
DIFFERENT GROUPS OF IMMUNOCOMPROMISED PATIENTS 
 FREQ PERCENTAGE 
CANCER CHEMOTHERAPY GROUP 11 17% 
POST RENAL TRANSPLANT GROUP 9 14% 
CHRONIC KIDNEY DISEASE GROUP 16 25% 
HAEMATOLOGICAL MALIGNANCIES 8 12% 
CONNECTIVE TISSUE DISEASES 21 32% 
TOTAL 65 100% 
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FIG 3: DIFFERENENT GROUPS OF IMMUNOCOMPROMISED PATIENTS 
PRESENTING SYMPTOMS 
The presenting symptoms of the patients were  
 CHEST SYMPTOMS ALONE: Consisted of cough with expectoration, 
dry cough, Dyspnea, Chest pain etc. 
 CHEST SYMPTOMS ALONG WITH FEVER 
 FEVER ALONE  
 HEMOPTYSIS 
 ASYMPTOMATIC  
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DIFFERENT GROUPS OF IMMUNOCOMPROMISED 
PATIENTS
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TABLE 6: PRESENTING SYMPTOMS 
PRESENTING SYMPTOMS 
 FREQ % 
CHEST SYMPTOMS ALONE  36 55% 
CHEST SYMPTOMS WITH FEVER 11 17% 
HEMOPTYSIS 9 14% 
FEVER ALONE  6 9% 
ASYMPTOMATIC 3 5% 
TOTAL 65 100% 
 
 
FIG 4: PRESENTING SYMPTOMS 
 
 
 
PRESENTING SYMPTOMS
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DURATION OF SYMPTOMS 
Duration of symptoms was divided into 4 groups: 
 ACUTE ONSET - < 3 weeks 
 SUBACUTE ONSET – 3-8 weeks 
 CHRONIC - > 8 weeks 
 ASYMPTOMATIC  
TABLE 7: DURATION OF SYMPTOMS 
DURATION OF SYMPTOMS 
 FREQ % 
< 3 WEEKS 34 52% 
3-8 WEEKS 20 31% 
> 8 WEEKS 8 12% 
ASYMPTOMATIC 3 5% 
TOTAL 65 100% 
 
 
FIG 5: DURATION OF SYMPTOMS 
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RADIOLOGICAL FINDINGS 
The radiological findings at the time of presentation were divided into followings 
groups based on the predominant pattern as assessed by the pulmonologist 
 Consolidation pattern, Ground Glass Opacities, Tree-in-Bud pattern, Cavity, 
Reticular & Nodular pattern. 
TABLE 8: RADIOLOGY 
DIFFERENT FORMS OF RADIOLOGICAL INVOLVEMENT 
 FREQ % 
CONSOLIDATION 31 48% 
GROUND GLASS OPACITIES  9 14% 
CAVITY 7 11% 
TREE IN BUD APPEARANCE  4 6% 
RETICULAR PATTERN 8 12% 
NODULAR PATTERN 6 9% 
TOTAL 65 100% 
 
 
FIG 6: DIFFERENT PATTERNS OF RADIOLOGICAL INVOLVEMENT 
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ALVEOLAR VS NON-ALEOLAR PATTERN 
Consolidation, GGO, Cavity, Tree in Bud were considered together as alveolar 
pattern and Reticular & Nodular predominant forms were considered as non-
alveolar pattern 
TABLE 9: ALVEOLAR VS NON-ALVEOLAR PATTERN 
ALVEOLAR VS NON-ALVEOLAR PATTERN 
 FREQ % 
ALVEOLAR PATTERN 51 79% 
NON-ALVEOLAR PATTERN 14 21% 
TOTAL 65 100% 
 
 
FIG 7: ALVEOLAR VS NON-ALVEOLAR PATTERN 
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LOBE INVOLVEMENT (CT CHEST) 
In our study lobe involvement was divided into Upper Lobe, Middle Lobe/ 
Lingula, Lower Lobe.  
TABLE: 10: LOBE INVOLVEMENT IN CT-CHEST 
LOBE INVOLVEMENT 
LOBE FREQ % 
UPPER LOBE 21 32% 
MIDDLE LOBE/ LINGULA 17 26% 
LOWER LOBE 27 41% 
TOTAL 65 100% 
 
FOCAL VS DIFFUSE INVOLVEMENT 
Involvement of single lobe was considered as focal & involvement of 2 or more 
lobes was considered as diffuse. 
 
FIG 8: FOCAL VS DIFFUSE INVOLVEMENT OF LOBES 
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YIELD OF BRONCHOSCOPY 
In our study bronchoscopy gave positive results in 80% (52 cases) and no 
diagnosis could be obtained even after bronchoscopy in 20% (13 cases) 
POSITIVE YIELD: Yield considered to be positive when infectious etiology 
like TB (diagnosed by Bronchial Wash GeneXpert/ AFB smear positivity), 
BACTERIAL, FUNGAL organisms were diagnosed by culture OR 
noninfectious causes were diagnosed by Histopathological examination & 
cytology. 
NEGATIVE YIELD: when no diagnosis could be obtained.   
 
FIG 9: YIELD OF BRONCHOSCOPY 
 
 
BRONCHOSCOPIC YIELD
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INFECTIOUS VS NON-INFECTIOUS ETIOLOGY DIAGNOSED BY 
BRONCHOSCOPY 
Out of the 80 % (52 cases) of positive bronchoscopic yield 65% (42) were due to 
infectious etiology and remaining 15% (10) were due to non-infectious causes. 
TABLE 11: YIELD OF BRONCHOSCOPY 
BRONCHOSCOPIC YEILD FREQ % 
INFECTOIUS ETIOLOGY 42 65% 
NON-INFECTIOUS ETIOLOGY 10 15% 
NO DIAGNOSIS OBTAINED 13 20% 
TOTAL 65 100% 
 
 
FIG 10: INFECTIOUS VS NON-INFECTIOUS ETIOLOGY – BY BRONCHOSCOPY 
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SPECTRUM OF PULMONARY INFECTIONS  
Among the infectious causes of pulmonary diseases in immunocompromised 
patients Bacterial infections were predominant with 24%, followed by mixed 
infections by 15%, tuberculosis 14% & fungal 12%  
TABLE 12: SPECTRUM OF PULMONARY INFECTIONS 
ORGANISM IDENTIFIED 
 FREQ % 
BACTERIAL ALONE 15 24% 
TUBERCULOSIS ALONE 9 14% 
FUNGAL ALONE  8 12% 
MIXED 10 15% 
NON-INFECTIOUS  10 15% 
NO DIAGNOSIS 13 20% 
TOTAL 65 100% 
 
 
FIG 11: SPECTRUM OF PULMONARY INFECTIONS 
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TYPES OF MIXED ORGANISMS IDENTIFIED 
TABLE 13: PATTERN OF MIXED ORGANISMS 
ORGANISMS FREQ 
TUBERCULOSIS + BACTERIAL 3 
TUBERCULOSIS + FUNGAL 2 
BACTERIAL + FUNGAL 4 
TUBERCULOSIS + BACTERIAL+ FUNGAL 1 
TOTAL 10 
 
 
FIG 12: SPECTRUM OF MIXED ISOLATES 
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SPECTRUM OF BACTERIAL INFECTIONS 
Overall out of 65 patients in the study bronchial wash bacterial culture was 
positive in 22 patients. In one patient two organisms were isolated. So totally 23 
organisms isolated contributing to 35% of infection in immunocompromised 
patients. 
TABLE 14: SPECTRUM OF BACTERIAL INFECTIONS 
BACTERIAL ISOLATES IDENTIFIED BY BAL CULTURE 
 FREQ % 
BACTERIAL ALONE 15 23% 
BACTERIAL + OTHER ORGANISMS (TB/ FUNGAL) 8 12% 
NEGATIVE FOR BACTERIAL CULTURE 42 65% 
TOTAL 65 100% 
 
 
FIG 13: PROPOTION OF BACTERIAL INFECTIONS DIAGNOSED BY BAL CULTURE 
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BAL BACTERIAL CULTURE RESULTS 
TABLE 15: BACTERIA ISOLATED FROM CULTURE 
BACTERIA ISOLATED 
 FREQ % 
STREPTOCOCCUS PNEUMONIAE 1 1.5% 
KLEBSIELLA PNEUMONIAE 5 7.5% 
PSEUDOMONAS AERUGINOSA 7 10.5% 
ACINETOBACTER  3 4.5% 
MRSA 5 7.5% 
ENTEROCOCCI 2 3% 
E. COLI 1 1.5% 
 
 
FIG 14: SPECTRUM OF BACTERIAL INFECTIONS 
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SPECTRUM OF FUNGAL INFECTIONS 
Out of 65 patients in whom BAL was done fungal culture was positive in 15 
cases, contributing to 23% of pulmonary infections. Out of 15 BAL fungal 
culture positive, in 8 patients, fungi were alone, isolated & in remaining 7 cases, 
fungi were isolated with other organisms (Bacterial/TB) 
TABLE 16: SPECTRUM OF FUNGAL INFECTIONS 
FUNGAL ORGANISMS ISOLATED FROM BAL CULTURE 
 FREQ % 
FUNGAL ALONE ISOLATED 8 12% 
FUNGAL + OTHER ORGANISMS 7 11% 
NEGATIVE FOR FUNGAL CULTURE 50 77% 
TOTAL 65 100% 
 
 
FIG 15: PROPORTION OF FUNGAL INFECTIONS IDENTIFIED BY BAL CULTURE 
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FUNGAL ORGANISMS GROWN IN BAL FUNGAL CULTURE 
TABLE 17: FUNGAL ORGANISMS 
FUNGAL ISOLATES IN BAL   
 FREQ % 
CANDIDA ALBICANS 2 3% 
CANDIDA TROPICALIS 1 1.5% 
CANDIDA PARASILOPSIS 1 1.5% 
PENICILLIUM MARNEFFI 1 1.5% 
ASPERGILLUS NIGER 4 6% 
ASPERGILLUS FUMIGATUS 3 4.5% 
ASPERGILLUS FLAVUS 2 3% 
ASPERGILLUS VERSICOLOR 1 1.5% 
 
 
FIG 16: SPECTRUM OF PULMONARY INFECTIONS 
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PROVEN / PROBABLE FUNGAL INFECTIONS VS COLONISERS 
Out of 15 cases of fungal infections diagnosed by BAL culture, Anti-Fungal 
drugs were started only in 9 patients. The remaining were thought to be due to 
colonizers in the bronchial tree.  
 
FIG 17: SPECTRUM OF FUNGAL INFECTIONS 
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SPECTRUM OF TUBERCULOUS INFECTIONS  
Out of 65 immunocompromised patients, 15 patients BAL GeneXpert MTB was 
detected, contributing to 24% of pulmonary infections. In 9 patients, tuberculosis 
alone was detected & and remaining 6 TB was detected with other organisms. 
TABLE 18: SPECTRUM OF TUBERCULOSIS 
TUBERCULOUS INFECTION DIAGNOSED IN BAL BY GENEXPERT 
 FREQ % 
TUBERCULOSIS ALONE 9 14% 
TUBERCULOSIS + FUNGAL 2 3% 
TUBERCULOSIS + BACTERIAL 4 6% 
TUBERCULOSIS + BACTERIAL + FUNGAL 1 1% 
NEGATIVE FOR TUBERCULOSIS 50 76% 
TOTAL 65 100 
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DRUG SENSITIVITY PATTERN AMONG TUBERCULOSIS 
INFECTION 
Out of 15 patients in whom Bronchial Wash GeneXpert MTB was detected 1 
showed rifampicin resistant, 1 showed indeterminate pattern, remaining were 
rifampicin sensitive.  
 
 
 
FIG 19: DRUG SENSITIVITY AMONG TUBERCULOSIS PATIENTS. 
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NON-INFECTIOUS ETIOLOGY DIAGNOSED BY BRONCHOSCOPY 
TABLE 19: NON-INFECTIOUS CAUSES 
NON-INFECTIOUS CAUSES OF PULMONARY INFILTRATES 
 FREQ % 
MALIGNANCY DIAGNOSED BY CYTOLOGY/ HPE 6 9% 
HOGKINS LYMPHOMA – LYMPHOMATOUS INFILTRATION 1 1.5% 
RADIATION FIBROSIS 1 1.5% 
ALVEOLAR HAEMORRHAGE 1 1.5% 
INTERSTITIAL FIBROSIS 1 1.5% 
TOTAL 10 15% 
 
 
FIG 20: SPECTRUM OF NON-INFECTIOUS CAUSES OF PULMONARY DISEASES 
 
 
 
 
NON-INFECTIOUS CAUSES
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COMPLICATIONS OF BRONCHOSCOPY 
Out of 65 immunocompromised patients in whom bronchoscopy was done for 
evaluation of pulmonary diseases 76% did not have any complications and in 
remaining 24% minor complications were present. 
TABLE 20: COMPLICATIONS OF FOB 
COMPLICATIONS OF BRONCHOSCOPY 
 FREQ % 
TRANSIENT HYPOXEMIA 10 15% 
MINOR BLEEDING 5 8% 
PNEUMOTHORAX 1 1% 
NO COMPLICATIONS 49 76% 
TOTAL 65 100% 
 
 
FIG 21: COMPLICATIONS OF BRONCHOSCOPY 
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CHANGE IN CURRENT EMPERICAL TREATMENT PLAN DUE TO 
BRONCHOSCOPIC INTERVENTION 
Out of 65 immunocompromised patients in whom FOB was done the current 
treatment plan was changed in 37 patients as the result of bronchoscopic 
intervention contributing to 57%. 
 
FIG 22:  CHANGE IN TREATMENT PLAN AS THE RESULT OF BRONCHOSCOPY 
 
TYPE OF TREATMENT MODIFICATION 
TABLE 21: TREATMENT MODIFICATION 
TYPE OF TREATMENT MODIFICATION CLINICAL IMPROVEMENT 
 FREQ % IMPROVEMENT 
 
% 
ATT STARTED 15 23% 11 75% 
ANTIBIOTICS 
CHANGED 
8 12% 7 90% 
ANTIFUNGALS 
STARTED 
9 14% 6 65% 
CHEMOTHERAPY 
RESTARTED 
5 8% 1 20% 
NO CHANGE  28 43%  
TOTAL 37 57% 
 
YES
57%
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CLINICAL IMPROVEMENT AS THE RESULT OF CHANGE IN 
EMPIRICAL TREATMENT 
Out of 37 patients in whom Bronchoscopy led to change in current treatment plan 
26 patients (71%) improved clinically and remaining 11 patients (29%) 4 patients 
died due to other comorbidities, 4 patients lost follow up and remaining 3 did not 
improve. 
TABLE 22: CLINICAL IMPROVEMENT IN FOLLOW UP 
CLINICAL IMPROVEMENT DUE TO CHANGE IN TREATMENT PLAN  
BRONCHOSCOPY  FREQ % 
IMPROVED CLINICALLY 26 71% 
DIED DUE TO COMORBIDITIES 4 11% 
LOST FOLLOW UP 4 11% 
NOT IMPROVED 3 8% 
TOTAL 37 100% 
 
 
FIG 23: CLINICAL IMPROVEMENT IN DUE TO CHANGE IN EMPIRICAL TREATMENT 
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BRONCHOSCOPIC EVALUATION OF PULMONARY DISEASES IN 
NON-HIV IMMUNOCOMPROMIED PATIENTS IN OUR STUDY – 
THE OVERALL PICTURE 
FIG24: BRONCHOSCOPIC EVALUATION OF PULMONARY DISEASES 
TABLE 23: OVERALL PICTURE – BRONCHOSCOPIC EVALUATION 
BRONCHOSCOPIC EVALUATION OF PULMONARY DISEASES 
 FREQ % 
BACTERIAL INFECTIONS ALONE 15 23% 
TUBERCULOSIS ALONE  9 14% 
FUNGAL ALONE  8 12% 
MIXED INFECTIONS/POLYMICROBIAL 10 15% 
MALIGNANCY 6 9% 
HOGKINS LYMPHOMA INFILTRATION 1 1.5% 
RADIATION FIBROSIS 1 1.5% 
ALVEOLAR HAEMORRHAGE 1 1.5% 
INTERSTITIAL FIBROSIS 1 1.5% 
NO DIAGNOSIS 13 20% 
TOTAL 65 100% 
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COMPARISON OF SYMPTOMS WITH YIELD ON BRONCHOSCOPY 
TABLE 24: SYMPTOMS VS YIELD 
SYMPTOMS YIELD ON BRONCHOSCOPY TOTAL 
(100%) 
POSITIVE NEGATIVE 
CHEST SYMPTOMS WITH FEVER 10 (91%) 1 (9%) 11 
CHEST SYMPTOMS ALONE 28 (78%) 8 (22%) 36 
HAEMOPTYSIS 8 (89%) 1 (11%) 9 
FEVER ALONE 6 (100%) 0 (0%) 6 
ASYMPTOMATIC 0 (0%) 3 (100%) 3 
TOTAL 52 13 65 
P VALUE 0.004 
 
 
FIG 25: COMPARISON OF SYMPTOMS WITH BRONCHOSCOPIC YIELD 
 Fever alone as presenting symptom gave a yield of 100%, followed by 
chest symptoms with fever with 91% 
 So the presence of fever (fever alone or chest symptoms with fever) 
increased yield to 95% when compared to other symptoms. In 
asymptomatic patients there was no yield.  
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SYMPTOMS VS YIELD
YIELD NEGATIVE YIELD POSITIVE TOTAL
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COMPARISON OF RADIOLOGICAL PRESENTATION OF 
BRONCHOSCOPIC YIELD 
TABLE 25: RADIOLOGY VS YIELD 
RADIOLOGICAL PRESENTATION YIELD ON BRONCHOSCOPY TOTAL 
 POSITIVE NEGATIVE  
CONSOLIDATION 27 (87%) 4 (13%) 31 
GROUND GLASS PATTERN 7 (78%) 2 (22%) 9 
TREE IN BUD PATTERN 3 (75%) 1 (25%) 4 
CAVITY 7 (100%) 0 (0%) 7 
RETICULAR/NODULAR PATTERN 8 (57%) 6 (43%) 14 
TOTAL 52 13 65 
 
 
FIG 26: RADIOLOGICAL PATTERN VS YEILD 
 Cavity had the highest yield of 100%, followed by consolidation with 87% 
 The reticular / Nodular pattern had the lowest yield of 57% out of which 55% 
were non-infectious and 45% were infectious. Infectious causes were due to 
34% tuberculosis and 11% bacterial. Noninfectious causes were malignancy, 
radiation fibrosis, interstitial pneumonia etc. 
RADIOLOGICAL PATTERN VS YIELD
YIELD POSITIVE YEILD NEGATIVE
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COMPARISON OF LOBE INVOLVEMENT IN RADIOLOGY TO 
YIELD 
TABLE 26: LOBE INVOLVEMENT VS YIELD 
LOBE INVOLVEMENT YIELD ON BRONCHOSCOPY TOTAL 
 POSITIVE NEGATIVE  
UPPER LOBE 20 (95%) 1 (5%) 21 
MIDDLE LOBE 12 (70%) 5 (30%) 17 
LOWER LOBE  20 (74%) 7 (26%) 27 
TOTAL 52 13 65 
 
 
FIG 27: COMPARISON OF LOBE INVOLEMENT TO BRONCHOSCOPIC YIELD 
 The upper lobe disease had a better yield of 95% compared to middle & the 
lower lobe involvement. 
 Focal involvement (involvement of one lobe) had a higher yield of 85% when 
compared to Diffuse disease (2 or more lobes) with 72% 
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COMPARISON OF YIELD IN BRONCHOSCOPY TO TREATMENT 
MODIFIED 
 80% (n=52) patients had a positive yield on bronchoscopy. 
 Based on bronchoscopy current treatment was modified in 57% (n=37) 
patients 
TABLE 27: YIELD VS TREATMENT MODIFICATION 
TREATMENT MODIFIED YIELD ON BRONCHOSCOPY TOTAL 
 POSITIVE NEGATIVE  
YES 37 (57%) 0 (0%) 37 (57%) 
NO 15 (23%) 13 (20%) 28 (43%) 
TOTAL 52 (80%) 13 (20%) 65 (100%) 
P VALUE 0.000 
 
 Out of 65 patients in whom FOB was done the current empirical treatment 
plan was changed in 37 patients (57%). 
 This was statistically significant with P value of 0.000 
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ANALYSIS OF DIFFERENT SUBGROUPS OF 
IMMUNOCOMPROMISED PATIENTS 
GROUP 1: CANCER PATIENTS RECEIVING CHEMOTHERAPY 
PRESENTING WITH NEW PULMONARY INFILTRATES 
 This group contributes to 17% (n=11) of the total population 
TABLE 28: SPLIT UP CANCER CHEMOTHERY GROUP 
CANCER CHEMOTHERAPY SUBGROUPS 
 FREQ % 
LUNG CANCER 1 1.5% 
ESOPHAGEAL 2 3% 
STOMACH 1 1.5% 
PHARYNGEAL 5 8% 
BREAST 2 3% 
 
SYMPTOM ANALYSIS 
 55% of patients presented predominantly with chest symptoms 
 Presence of fever was less in this group. Only 27% had fever at the time of 
presentation & remaining 72% was afebrile. 
DURATION OF SYMPTOMS 
 18% had acute/short duration of symptoms (< 3 weeks) remaining 72% had 
symptoms for more than > 3 weeks. When compared to other groups cancer 
group had longer duration of symptoms possibly because of more non-
infectious nature of pulmonary disease. 
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TABLE 29: DURATION OF SYMPTOMS 
 
RADIOLOGICAL PRESENTATION 
 46% of patients presented with consolidation followed by nodular pattern in 
36%. 
TABLE 30: RADIOLOGICAL PRESENTATION 
DIAGNOSIS RADIOLOGICAL PRESENTATION TOTAL 
 CONSOLIDATION CAVITY NODULAR RETICULAR TREE 
IN 
BUD 
GGO  
CANCER 
GROUP 
5 (46%) 2 (18%) 4 (36%) 0 0 0 100% 
OTHERS 28 (48%) 5 (9%) 2 (4%) 8 (15%) 4 (7%) 9 
(16%) 
100% 
P VALUE                                                0.008 
 
 Nodular involvement in this group was 36% compared to only 4% in other 
groups. This was statistically significant with P value 0.008 
 Focal involvement was seen in 82% as against diffuse involvement (2 or more 
lobes) seen only in 18%. 
DIAGNOSIS DURATION OF SYMPTOMS TOTAL 
 ASYMPYOMATIC < 3 
WEEKS 
3-8 
WEEKS 
> 8 
WEEKS 
 
CANCER GROUP 0 2 (18%) 4 (36%) 5 (46%) 100% 
OTHER GROUPS 3 (5%) 28 (59%) 20 (30%) 3 (6%) 100% 
P VALUE                             0.001 
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 Middle lobe/ Lower lobe involvement was seen equally in 36% each, with 
Upper lobe involvement in 27%. 
DIAGNOSIS OF PULMONARY INFILTRATES 
In cancer only 36% of pulmonary lesions were infective remaining 64% non-
infectious cause. In other groups, non-infectious cause contributed to only 6%. 
This was statistically significant with chi-square P value 0.000 
 
FIG 28: PULMONARY DISEASE IN CANCER GROUP VS OTHER GROUPS 
ETIOLOGICAL DIAGNOSIS OF PULMONARY DISEASES.  
 Among non-infective causes 54% (n=6) were due to malignancy & 9% (n=1) 
was due to RADIATION FIBROSIS 
• Out of infective etiology TB – 9% (n=1) BACTERIAL – 9 (n=1) & FUNGAL 
– 18% (n=2) (Aspergillus Niger & fumigatus) 
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INFECTIVE 36% 70%
NON-INFECTIVE 64% 6%
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PULMONARY INFILTRATES IN CANCER GROUP VS 
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FIG 29: ETIOLOGICAL DIAGNOSIS OF PULMONARY DISEASES IN CANCER GROUP 
TREATMENT MODIFICATION & CLINICAL IMPROVEMENT IN 
CANCER PATIENTS BASED ON BRONCHOSCOPIC RESULTS 
 Based on bronchoscopic results, 55% of patients, their current treatment 
regimen was changed. 
 10%(1 patient) ATT was started, 20%(2 patient) Antifungals started, 27%(3 
patient) in whom second line chemotherapy regimens started none improved 
possibly because of their advanced nature of disease. 
Overall, only 36% patients clinically improved when compared to other 
groups with 80% clinical improvement with a change in treatment.  This was 
statistically significant with P value 0.003.  This was because of possible 
advanced nature of underlying malignancy at time of presentation.  
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TABLE 30: CLINICAL IMPROMENT CANCER VS OTHERS 
DIAGNOSIS CLINICAL IMPROVEMENT WITH 
CHANGE IN TREATMENT 
 
 IMPROVED NOT IMPROVED TOTAL 
CANCER GROUP 4 (36%) 7 (64%) 11 
OTHERS 43 (80%) 11 (20%) 54 
P VALUE  0.003  
 
 
COMPLICATIONS OF BRONCHOSCOPY  
 The most common complication was moderate bleeding due to biopsies. 
 Mild to moderate bleeding episodes which was controlled by wedging the 
bleeding site and applying pressure and instillation of cold saline. 
 Minor bleeding episodes in this group is 27% compared to other groups 
with 4%, which is statistically significant with P value 0.031 
FIG 30: COMPLICATIONS DURING FOB - CANCER GROUP VS OTHERS  
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GROUP 2: POST RENAL TRANSPLANT PATIENTS RECEIVING 
IMMUNOSUPPRESIVE DRUGS 
 This group contributing to 13.8% (n=9) of the total population  
SYMPTOM ANALYSIS 
 67% patients had fever with or without chest symptoms at time of 
presentation compared to 20% in other groups. 
 This was statistically significant with P value 0.003 
 
FIG 31: SYMPTOM ANALYSIS – RENAL TRANSPLANT VS OTHER GROUPS 
 89% presented acutely (<3 weeks) of symptoms, only 11% had symptoms 
more than 3 weeks. 
TABLE 31: DURATION OF POST RENAL TRANSPLANT 
DURATION OF POST RENAL TRANSPLANTATION NUMBER 
< 1 MONTH 3 
1-6 MONTHS 2 
> 6 MONTHS 4 
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OTHER SYMPTOMS
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FEVER 67% 20%
OTHER SYMPTOMS 33% 80%
67%
20%
33%
80%
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RADIOLOGICAL INVOLVEMENT 
 67% presented with a consolidation pattern followed by 22% with GGO 
pattern. 
 55% had predominant lower lobe disease followed by 33% with Upper lobe 
involvement 
 67% had focal infiltrates and remaining 33% had diffuse disease. 
DIAGNOSTIC YEILD OF BRONCHOSCOPY 
 Out of 9 patients, 8 had a positive yield (89%) contributing 17% of overall 
positive yield. 
PULMONARY INFECTIONS IN POST RENAL TRANSPLANT GROUP 
TABLE 32: SPECTRUM OF PULMONARY INFECTIONS 
ETIOLOGY OF PULMONARY INFECTIONS FREQ % 
NO DIAGNOSIS 1 11% 
TUBERCULOSIS 1 11% 
FUNGAL  1 11% 
BACTERIAL 4 45% 
MIXED (BACTERIAL + FUNGAL) 2 22% 
NON-INFECTIVE  0 0% 
TOTAL 9 100% 
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FIG 29: PULMONARY INFECTIONS IN POST RENAL TRANSPLANT GROUP 
PULMONARY INFECTIONS IN POST RENAL TRANSPLANT 
PATIENTS 
TABLE 33: ORGANISMS ISOLATED 
ORGANISMS ISOLATED FREQUENCY 
KLEBSIELLA SP 1 
PSEUDOMONAS SP 2 
ACINETOBACTER SP 2 
MRSA 1 
CANDIDA ALBICANS 1 
CANDIDA PARASILOPSIS 1 
ASPERGILLUS NIGER 1 
TUBERCULOSIS 1 
 
 
NO DIAGNOSIS, 1, 
11%
TB, 1, 11%
BACTERIAL, 4, 45%
FUNGAL, 1, 11%
MIXED, 2, 22%
ETIOLOGY OF PULMONARY INFECTIONS  IN POST RENAL TRANSPLANT 
GROUP
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BACTERIAL INFECTIONS IN RENAL TRANSPLANT GROUP 
COMPARING WITH OTHER GROUPS 
Bacterial infections were more common in this group, 67% compared to 
other groups. 
 
FIG 30: BACTERIAL INFECTIONS ACROSS DIFFERENT GROUPS 
SPECTRUM OF PULMONARY INFECTIONS ACCORDING TO 
DURATION OF POST RENAL TRANSPLANT  
TABLE 34: TRANSPLANT DURATION VS PULMONARY INFECTIONS 
DURATION OF POST RENAL 
TRANSPLANT 
NO 
YEILD 
TB BACTERIAL FUNGAL MIXED 
< 1 MONTH 0 0 2 (67%) 1(33%) 0 
1-6 MONTHS 1(50%) 0 1(50%) 0 0 
> 6 MONTHS 0 1(25%) 1(25%) 0 2(50%) 
 
BACTERIAL INFECTIONS ACROSS DIFFERENT GROUPS
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 Immediately POST TRANSPLANT PERIOD (< 1MONTH) bacterial 
infections are more predominant. 
 > 6 Months after transplant or after a longer duration of 
immunosuppression Tuberculosis was more common in our study. 
TREATMENT MODIFICATION AND CLINICAL IMPROVEMENT 
BASED ON BRONCHOSCOPIC YEILD 
 66% (n=6) of patients, their current empirical treatment modality was 
changed based on bronchoscopic results. ATT started in 11% (n=1), 
antibiotics changed in 33% (n=3) antifungals started in 22% (n=2) 
COMLICATIONS OF BRONCHOSCOPY 
 
FIG 31: COMPLICATIONS BETWEEN RENAL TRANSPLANT GROUP AND OTHERS 
• Overall complications were more in the renal transplant group.  
 Transient hypoxemia was frequently observed (55% vs 9% in the rest). 
Statistical significance was P value 0.004 
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GROUP 3: CHRONIC KIDNEY DISEASE PATIENTS ON 
MAINTANENCE HAEMODIALYSIS 
 This group contributing to 25% (n=16) of the total population studied. 
 Bronchoscopic yield was obtained in 69% (n=11) contributing to the overall 
yield of 21%. 
SYMPTOM ANALYSIS IN CKD GROUP  
 62.5% presented with chest symptoms followed by 25% with Haemoptysis.  
 Presence of fever was lesser in this group similar to cancer groups 
  63% patients presented with acute symptomatology (< 3 weeks) and 
remaining 37% with subacute presentation (3-8 weeks). 
 
 
FIG 32: PRESENTING SYMPTOMS IN CKD GROUP 
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RADIOLOGICAL PRESENTATION 
 
FIG 33: RADIOLOGICAL PRESENTATION CKD GROUP 
 The predominant radiological pattern was consolidation occurring in 75%, 
followed by GGO pattern with 19%. 
COMPARISON OF ALVEOLAR PATTERN/ NON-ALVEOLAR 
PATTERN IN CKD VS OTHER GROUPS. 
TABLE 35: RADIOLOGICAL PRESENTATION – CKD VS OTHERS 
DIAGNOSIS RADIOLOGICAL PRESENTATION  
 NON-ALVEOLAR 
PATTERN 
ALVEOLAR 
PATTERN 
 
CKD GROUP 0 16 (100%) 16 (100%) 
OTHERS 14 (29%) 35 (71%) 49 (100%) 
TOTAL 14 35 65 
P VALUE 0.016 
 
 All patients had an alveolar pattern in radiology like when compared to 
71% in other groups which was statistically significant with P value 0.016 
CONSOLIDATION
GGO
TREE IN BUD
CAVITY
RETICULONODULAR
RADIOLGICAL PRESENTATION IN CKD GROUP
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DIAGNOSTIC YEILD IN CKD GROUP 
 The diagnostic yield in this group was 69% (n=11) 
 There were no non-infective causes like in the renal transplant group. 
SPECTRUM OF PULMONARY INFECTIONS IN CKD PATIENTS 
TABLE 36: PATTERN OF PULMONARY INFECTIONS - CKD 
PULMONARY INFECTIONS IN CKD GROUP FREQ % 
TUBERCULOSIS 2 12% 
BACTERIAL 3 19% 
FUNGAL 2 13% 
MIXED 4 25% 
NO DIAGNOSIS 5 31% 
 
 
FIG 34: PULMONARY INFECTIONS IN CKD 
 Out of mixed infections 3 were due to tuberculosis. (Tuberculosis + 
Bacteria – 1, Tuberculosis + Fungal – 2, Bacterial + Fungal – 1) 
TB, 2, 12%
BAC, 3, 19%
FUNGAL, 2, 13%
TB + BAC, 1, 6%
TB + FUNGAL, 2, 
13%
BAC + FUNGAL, 
1, 6%
NO DIAGNOSIS, 
5, 31%
PULMONARY INFECTIONS IN CKD
76 
 
TABLE 37: TYPES OF MICROORGANISMS 
MICROORGANISM FREQUENCY 
TUBERCULOSIS 5 
KLEBSIELLA SP 2 
PSEUDOMONAS SP 1 
ACINETOBACTER SP 1 
ENTEROCOCCI 1 
CANDIDA TROPICALS 1 
PENICILLUM SP [ ANNEXURE 2] 1 
ASPERGILLUS NIGER 1 
ASPERGILLUS FLAVUS  2 
 
TREATMENT MODIFICATION AND CLINICAL IMPROVEMENT 
BASED ON BRONCHOSCOPIC YEILD 
 Empirical Treatment was modified in 56% (n=9) of patients. Anti-
tuberculous therapy started in 30% (n=5), antibiotic regimen changed in 
12.5% (n=2) and anti-fungal drug started in 12.5% (n=2).  
 75% (n=6) in whom empirical treatment was modified improved clinically. 
COMLICATIONS OF BRONCHOSCOPY 
 Overall complications were seen in 37% (n=6) in this group. 
• The predominant complication was transient hypoxemia, which required 
oxygen therapy during and after procedure in 31% (n=5). 
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GROUP 4: PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES  
 This group contributed about 12% (n=8) of the total population. 
 Bronchoscopic yield was 75% and contributing to an overall yield of 12%. 
TYPES OF HAEMATOLOGICAL MALIGNANCY PATIENTS 
TABLE 38: SPLIT UP OF HEMATOLOGICAL MALIGNANCY PATIENTS 
DIAGNOSIS FREQ % 
ACUTE MYELOID LEUKEMIA 4 6% 
HODGKINS LYMPHOMA 3 4.5% 
NON-HODGKINS LYMPHOMA 1 1.5% 
 
SYMPTOM ANALYSIS 
 
FIG 35: PRESENTING SYMPTOMS IN PATIENTS HAEMTOLOGICAL MALIGNANCY 
 Chest symptoms were main presenting symptoms with 50%, followed by 
25% with fever & remaining 25% were asymptomatic 
CHEST 
SYMPTOMS, 4, 
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FEVER, 2, 25%
ASYMPTOMATIC
, 2, 25%
PRESENTING SYMPTOMS
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RADIOLOGICAL PRESENTATION 
 63% presented with an alveolar pattern (consolidation, GGO, cavity) 
 Upper lobe involvement was seen in 62.5% with Middle lobe/Lingular 
involvement in 25% and Lower lobe involvement in 12.5%. 
 Focal involvement was seen in 87.5% and Diffuse involvement 12.5%. 
 
FIG 36: RADIOLOGICAL PATTERNS IN HAEMATOLOGICAL MALIGNACY GROUP 
DIAGNOSTIC YIELD 
 A positive diagnostic yield is FOB was obtained in 75% (n=6)  
 62.5% (n=5) were infectious and 12.5% (n=1) were non-infectious.  
 The noninfectious case was a Lymphomatous infiltration in a patient with 
Hodgkin’s Lymphoma presenting with right upper lobe consolidation, which 
was proven by Trans Bronchial lung biopsy [refer Annexure 1] 
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SPECTRUM OF PULMONARY INFECTIONS 
 
FIG 37: PULMOARY INFECTIONS IN HAEMATOLOGICAL MALIGNANCY 
TABLE 39: ORGANISMS IDENTIFIED – HEMATOLOGICAL MALIGNANCY 
ORGANISMS FREQUENCY 
KLEBSIELLA SP 1 
ASPERGILLUS NIGER 1 
ASPERGILLUS FUMIGATUS  1 
CANDIDA ALBICANS  1 
TUBERCULOSIS 1 
 
TREATMENT MODIFICATION AND CLINICAL IMPROVEMENT 
BASED ON BRONCHOSCOPIC RESULTS  
 Treatment was modified in 50% (n=4) based on bronchoscopic results. ATT 
started in 12.5% (n=1), anti-fungal started in 25% (n=2), chemotherapy 
restarted in 12.5% (n=1). All patients in whom treatment was modified based 
improved clinically  
TB, 1, 12%
BAC, 1, 12%
FUNGAL, 3, 38%
MALIGNANCY, 1, 
13%
NO DIAGNOSIS, 
2, 25%
SPECTRUM OF PULMONARY INFECTIONS
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GROUP 5: CONNECTIVE TISSUE DISEASE (CTD) PATIENTS ON 
CORTICOSTEROIDS/IMMUNOSUPPRESIVE DRUGS/BIOLOGICAL 
AGENTS 
 This group constituted around 32% (n=21) of the total studied population. 
 71% (n=15) patients had a positive yield on bronchoscopy contributing to the 
overall yield of 28%. 
SUBTYPES OF CONNECTIVE TISSUE DISEASE PATIENTS 
 
FIG 38: SUBGROUPS OF CONNECTIVE TISSUE DISEASE PATIENTS 
TYPES OF IMMUNOSUPPRESIVE DRUGS RECEIVED 
 CORTICOSTEROIDS:  Patients received Prednisolone at a dose of > 20 
mg/day on a long term basis, at least for a period of more than 4 weeks. 
 OTHER IMMUNOSUPPRESIVE DRUGS: Includes patients receiving a 
combination of immunosuppressive drugs like weekly doses of Methotrexate/ 
Daily doses of Azathioprine/ Daily doses of Mycophenolate Mofetil/ 
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SUBGROUPS OF CTD PATIENTS
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Cyclophosphamide on intermittent monthly doses along with or without 
corticosteroids. 
 BIOLOGICAL AGENTS: Three patients received RITUXIMAB a 
monoclonal antibody against anti CD 20 for treatment of Rheumatoid 
Arthritis. 
 
FIG 39: TYPES OF IMMUNOSUPPRESIVE DRUGS RECEIVED 
SYMPTOM ANALYSIS 
• Most patients presented with chest symptoms like breathlessness, dry cough, 
because of the predominant pulmonary interstitial lung disease. 
• Presence of fever was less common in this group 
• Only 19% had fever with or without chest symptoms at time of presentation 
as compared to 81% who did not have fever, possibly because of high level 
of immune suppression induced by drugs. 
STEROIDS 
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IMMUNOSUPPRE
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BIOLOGICALS, 3, 
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FIG 40: SYMPTOMS IN CTD PATIENTS 
DURATION OF SYMPTOMS 
TABLE 40: SYMPTOM DURATION - CTD 
DURATION PERCENTAGE 
ASYMPTOMATIC 5% (1) 
0-3 WEEKS 52% (11) 
3-8 WEEKS 33% (7) 
> 8 WEEKS 10% (2) 
 
 More than 50% of patients had an acute presentation with symptoms of < 3 
weeks duration. Remaining 43% had longer duration of symptoms and 5% 
were asymptomatic referred with lesion in chest radiography. 
RADIOLOGICAL PATTERN IN CTD GROUP 
 The most common radiological pattern in this group is the reticular pattern 
due to the presence of underlying interstitial lung disease. 
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FIG 41: RADIOLOGICAL PATTERNS IN CTD GROUP 
TABLE 41: RADIOLOGICAL PATTERN CTD VS OTHERS 
 
DIAGNOSIS 
RADIOLOGICAL PATTERN 
CONSOLIDATION CAVITY GGO NODULAR RETICULAR TIB 
CTD 
GROUP 
29% (6) 14% (3) 14% 
(3) 
0% 33% (7) 10% 
OTHERS 
GROUPS 
57% 10% 14% 14% 2% 5% 
P VALUE 0.004 
 
LOBE INVOLVEMENT IN CTD GROUP  
 Lower involvement was most common 43%, followed by upper lobe 21%, 
Middle lobe/Lingular involvement in 17% 
 Focal involvement was seen in 52% and diffuse involvement in 48%. 
 
 
RETICULAR 
PATTERN, 7, 33%
CONSOLIDATION, 
6, 29%
CAVITY, 3, 14%
GGO, 3, 14%
TREE IN BUD, 2, 
10%
RADIOLOGICAL PATTERN IN CTD GROUP
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TABLE 42: LOBE INVOLVEMENT CTD VS OTHER GROUPS 
DIAGNOSIS LOBE INVOLVEMENT 
FOCAL DIFFUSE 
CTD GROUP 52% 48% 
OTHER GROUPS 81% 18% 
P VALUE 0.013 
• In CTD group diffuse disease is more common than other groups 
(48% vs 18%). This was statistically significant P value 0.013. 
SPECTRUM OF PULMONARY DISEASES IN CTD GROUP 
 
FIG 42: PULMONARY INFILTRATES IN CTD GROUP 
TABLE 43: SPECTRUM OF PULMONARY DISEASES - CTD 
PULMONARY DISEASES FREQUENCY 
TUBERCULOSIS ALONE  19% (4) 
BACTERIAL ALONE  24% (5) 
MIXED INFECTIONS  19% (4) 
INTESTITIAL FIBROSIS 5% (1) 
ALVEOLAR HAEMORRHAGE  5% (1) 
NO YIELD 28% (6) 
TB, 4, 19%
BAC, 5, 24%
TB + BAC + FUN, 1, 
5%
TB +  FUN, 2, 9%
BAC + FUN , 1, 5%
FIBROSIS, 1, …
ALV 
HAEMORRHAGE, 1, 
5%
NO YIELD, 6, 28%
PULMONARY INFILTRATES IN CTD PATIENTS
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TABLE 44: MICROORGANISMS ISOLATED AND THEIR FREQUENCY 
MICROORGANISM FREQUENCY 
PSEUDOMONAS SP 3 
MRSA 3 
ENTEROCOCCI 1 
E. COLI 1 
PSEUDOMONAS + MRSA 1 
ASPERGILLUS FUMIGATUS 1 
ASPERGILLUS VERSICOLOR 1 
TUBERCULOSIS 7 
 
COMPLICATIONS OF BRONCHOSCOPY 
 95% of patients did not have any complications.  
 The only one complication was due to pneumothorax, which developed 
during Trans Bronchial Biopsy, which needed ICD insertion.  
 Overall complications in this were less when compared to other groups.   
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DISCUSSION 
Sixty-five Non-HIV immunocompromised patients with pulmonary diseases 
were studied. They were divided into 5 groups, namely Cancer chemotherapy 
group, Post Renal Transplant Group, Chronic Kidney Disease on Haemodialysis, 
hematological malignancies & Connective tissue diseases on 
immunosuppresants.  
The main goal of our study was to evaluate the diagnostic utility of early 
bronchoscopy in non-HIV immunocompromised patients and the therapeutic 
utility in terms of treatment modification and clinical improvement as the result 
of bronchoscopic intervention.  
This is the first kind of study done in of Non-HIV immunocompromised 
population at our tertiary care hospital. The purpose of doing the study was 
because of lack of Studies done in our Indian population on bronchoscopic 
evaluation of pulmonary diseases especially in Non-HIV immunocompromised 
patients. Studies are only available in different subgroups like hematological 
malignancies, CKD, renal transplant recipients etc. With better chemotherapeutic 
drug availability for management of malignancies, well-functioning organ 
transplant programs, increased use of potent immunosuppresive drugs and newer 
biological agents for managing connective tissue diseases, more people are made 
immunocompromised for therapeutic reasons for management of their primary 
diseases. Ultimately more and more patients are developing pulmonary diseases 
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and the number of referrals are being increased to the Pulmonology department 
for their management. 
 Most of these patients are already been treated empirically with multiple potent 
antimicrobial drugs before being our Pulmonary medicine department. There is 
also increasing demand from other departments to start empirical 
Antituberculosis Treatment once patient does not improve with empirical 
antimicrobial therapy. Even some of the non-infectious causes like pulmonary 
edema, alveolar hemorrhage, malignancy are misdiagnosed and treated as 
infectious empirically. Because of this empirical treatment approach, there is 
increased economic burden, toxicity of antimicrobial therapy, increased 
incidence of multidrug resistant organisms and delay in starting proper treatment. 
This study highlights the role of early bronchoscopy in immunocompromised 
patients with pulmonary diseases that are not improving with empirical treatment 
with regards to its diagnostic yield, safety and change in empirical treatment. 
Patients were also followed up to look for clinical improvement.  
AGE DISTRIBUTION 
The mean age of the patients was 41.91 with a standard deviation of 15.5. The 
age of patients ranged from 15 years – 74 years. The patients were equally 
divided among two age groups < 40 years & > 40 years with 51% and 49% 
respectively. The bronchoscopic yield was almost similar in both age groups with 
81% in < 40 years and 78% in > 40 years. There was no statistical difference in 
yield, symptomatology, radiology or infections in both groups. 
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GENDER DISTRIBUTION 
 Out of 65 patients included in study 36 were male and 29 were females. Thus, 
ratio was 55% & 45% male to female. 
SYMPTOMATOLOGY 
Chest symptoms alone were the most common presentation with 55%, followed 
by chest symptoms along with fever in 17%. 5% of patients were asymptomatic. 
Presence of fever gave a higher overall yield of 95%. In asymptomatic patients, 
yield was zero. The statistical significance in chi-square P value was 0.004. 
Kyle R. Brownback et al., 55 observed similar finding where the diagnostic yield 
was significantly improved in the presence of fever.   
DURATION OF SYMPTOMS 
52% of patients presented with acute symptoms < 3 weeks, followed by 31% 
with symptoms 3-8 weeks duration and 12% with > 8 weeks duration. 5% were 
asymptomatic. Cancer chemotherapy group had longer duration of symptoms 
(72% with symptoms > 3 weeks duration) at the time of presentation. Post renal 
transplant (89%) & CKD patients (69%) more often had shorter duration of 
symptoms (< 3 weeks). The statistical significance was P value < 0.05.  The 
reason for more acute presentation in renal transplant and CKD group is because 
the pulmonary diseases were more of infectious etiology especially bacterial. In 
cancer group the disease process was mainly malignant infiltration hence fever 
was absent and they presented more gradually.  
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RADIOLOGICAL PATTERNS 
Consolidation was the predominant pattern seen in 48%, followed by GGO with 
14%, reticular pattern 12%, cavity 11%, nodular 9% and tree in bud 6%. Cavitary 
disease had a maximum yield of 100%, followed by consolidation with 87%. 
Reticular pattern had the lowest yield of 57%. Yield was better in an alveolar 
pattern of involvement in radiography.   
Kyle R. Brownback et al., 55 & Danes et al 33., in their study also had similar 
findings, unilateral & alveolar pattern in radiography had a better diagnostic 
yield.  
LOBE INVOLVEMENT  
Lower lobe involvement was most common with 41% followed by upper lobe 
with 32% and middle lobe/lingula with 26%. Focal involvement (single lobe) 
was more common with 78%. Yield was better in upper lobe involvement & focal 
involvement with 95% & 85% respectively. 
YIELD OF BRONCHOSCOPY 
The overall yield of bronchoscopy in our study was 80% with no diagnosis 
obtained in remaining 20%. 65% were due to infectious causes and 15% were 
due to non-infectious etiology. Similar studies done in immunocompromised 
patients have shown wide variations in overall yield ranging from 50-80%. But 
in most of the studies yield has been high for an infectious etiology ranging from 
60-80% similar to our study.33,34,56, 57 
90 
 
In a similar study done by Jain, P et al., 58 in 104 Non-HIV immunocompromised 
patients, the overall yield was 56.2% with high yield for an infectious etiology 
with 81%. 
A similar study done in the Indian population of Menon LR, et al., 59.  He studied 
16 renal transplants, 14 dialysis, 8 HIV positive patients, and the clinical utility 
of BAL in diagnosis of pulmonary infections. The overall yield was 76% of all 
the three groups put together. BAL cytology had a better yield when compared 
to culture. 
SPECTRUM OF PULMONARY INFECTIONS 
Our study results showed that in our tertiary care hospital among the 
immunocompromised patients bacterial infections were the predominant cause 
of pulmonary infections (35% overall, 23% by bacterial alone and 12% of 
bacterial + other organisms). Among the bacterial isolates Pseudomonas was the 
most common, followed by equally by Klebsiella and MRSA. This pattern is 
similar to the microbiological spectrum of Hospital acquired pneumonia where 
Gram negative organisms and MRSA are more common. These results are in 
accordance with several other published studies. 15,8 A similar study done by 
Rano et al 8., showed the same results as our study. He observed in his study 
bacterial infections caused by MRSA and gram negative bacilli especially 
Pseudomonas were the most common cause of pulmonary infections. Since 
bacteria represent the most prevalent threat to immunocompromised patients, 
each institution should define the empirical antibiotic treatment based on its own 
data.  
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Tuberculosis was the second most common infectious cause (24% overall, TB 
alone 14% and TB + Others organisms 10%). In spite of excluding sputum AFB 
positive cases from the study, still the incidence of tuberculosis is quite high in 
our study. This highlights the importance of thoroughly searching for pulmonary 
tuberculosis among non-HIV immune compromised patients with pulmonary 
disease in high prevalence countries even if the sputum AFB smear is negative. 
 Jane C. Chan et al.,27 in his study conducted in Hong Kong among 62 non-HIV 
immunocompromised patients found a similar result with tuberculosis being the 
second most common infection with a 19% incidence.  
When compared with CBNAAT (gene Xpert) BAL AFB staining was able to 
detect only 53% of smear negative pulmonary tuberculosis cases in our study.  
Moreover, CBNAAT gives the added advantage of detecting Rifampicin 
resistance and the results are available within a few hours when compared to 
conventional culture which takes 8-12 weeks. Hence CBNAAT should be offered 
upfront to all non-HIV immunocompromised patients with pulmonary disease 
for diagnosis of pulmonary tuberculosis. In our study only 6% case of pulmonary 
tuberculosis was Rifampicin resistant, 7% showed indeterminate resistance and 
remaining 87% cases were rifampicin sensitive.  
BAL fungal culture was positive in 23% (15 cases) in our study. But among 
fungal culture positive cases only 60% (9 cases) were diagnosed as proven or 
possible fungal infections requiring antifungal treatment as per the EORTC 
diagnostic criteria. In remaining 40% (6 cases) the isolated fungi from BAL 
culture could not be attributed to causing pulmonary disease as per diagnostic 
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criteria. These fungi might have colonized in the tracheobronchial tree without 
producing pulmonary lesions.  
Among 6 patients in whom fungi were considered as colonizers 3 patients had 
co-infection with tuberculosis and one patient with bacteria for which they 
received treatment. In remaining 2 patients no other co-infection could be 
identified. From a CKD patient Candida tropicalis was isolated in culture and 
Candida albicans was isolated in BAL in AML patient. The significance of these 
colonizers fungi is not fully understood. Some studies have shown poor clinical 
outcomes in respiratory tract Candida colonization and is independently 
associated with increased hospital mortality 22,23. 
 Aspergillus species was the most common fungi isolated from respiratory tract 
of non-HIV immunocompromised patients in our study. Among Aspergillus 
species Niger was the most common, followed by Fumigatus. 
Similar studies 15,8, 33 done in Non HIV immunocompromised patients show that 
among fungal infections Aspergillus is most common similar to our study.  
Bacterial infections were more common among Renal Transplant Recipients 
(67%) & Fungal infections were more common among hematological 
malignancy (38%) patients and Tuberculosis was more common among CTD 
(38%) patients followed by CKD (31%) group.   
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NON-INFECTIOUS CAUSES OF PULMONARY INFILTRATES 
In our study, 15% of pulmonary infiltrates were due to non-infectious causes. 
Among them most common cause (9%) was malignancy diagnosed by cytology 
or endobronchial biopsy and the remaining (6%) were due to radiation fibrosis, 
alveolar hemorrhage, interstitial pneumonia & lymphomatous infiltration of the 
lung in a case of secondary pulmonary lymphoma. 
COMPLICATIONS OF BRONCHOSCOPY  
Complications of bronchoscopy in our study were only minor except one case of 
pneumothorax which required ICD insertion. The overall complication rate was 
24%. Transient hypoxemia during and within the first hour of bronchoscopy, 
which required supplemental oxygen occurred in 15%, followed by mild to 
moderate bleeding episodes during biopsy procedures occurred in 8%. Bleeding 
controlled by wedging the bronchoscope at the site of bleeding and cold saline 
instillation. Pneumothorax occurred in 1%. 
Similar studies have shown the complication rate among non-HIV 
immunocompromised patients ranging from 13%-21%. 15,58 But complications 
were only minor in our study. But overall the complication rate of bronchoscopy 
is higher in immunocompromised patients. In general population, studies have 
shown the complication rate ranging widely from 5%-32%, with serious 
complication in 1.1% and mortality of 0.02% 45,60, 61.  There was no procedure 
related mortality in our study. Hence the proper pre procedural evaluation, patient 
selection and monitoring & care during/post procedure is necessary.  
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TREATMENT MODIFICATION & CLINICAL IMPROVEMENT 
In our study empirical treatment was modified to the most appropriate treatment 
in 57% of patients based on bronchoscopic results which was statistically 
significant with P value 0.000 Studies have shown similar results like our study 
where treatment modification based on bronchoscopic yield has ranged from 
38%-51%. 59,62,63 The treatment modification rate was higher in our study 
compared to other studies.  
Among patients in whom treatment was modified, those in whom antibiotic were 
changed as per culture sensitivity pattern showed maximum clinical 
improvement with 90%, followed by those in whom anti tuberculosis treatment 
was started showed 70% improvement and those in whom antifungals were 
started 60% clinical improvement. Those patients in whom malignancy was 
diagnosed and second line chemotherapeutic agents restarted only 20% showed 
clinical improvement probably because of their advanced nature of the disease. 
The overall clinical improvement with treatment modification was around 70%.  
SALIENT POINTS OBSERVED AMONG CANCER CHEMOTHERAPY 
PATIENTS IN OUR STUDY 
 Pulmonary disease in this group was more commonly due to non-infectious 
etiology that is malignancy. 
 Because of their non-infectious nature presence of fever at the time of 
presentation was lower, most patients had longer duration of symptoms. 
 The nodular pattern was a most common radiological pattern. 
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 The clinical improvement with treatment modification was low. 
 Bleeding was the most common complication which could be explained 
because of increased endobronchial biopsy done to achieve a diagnosis 
SALIENT POINTS IN POSTRENAL TRANSPLANT GROUP IN OUR 
STUDY 
 Fever was the predominant presenting symptom, most patients had acute 
symptoms at time of presentation 
 Overall Bacterial infections were more common 
 Immediate post-transplant period, bacterial infections were more, TB & 
fungal infections were more common after prolonged immunosuppression > 
6 months 
 Overall clinical improvement with change in treatment is good 
 Transient hypoxemia during bronchoscopy was frequently encountered 
SALIENT FINDINGS IN CKD GROUP 
 Chest symptoms and hemoptysis are more common. Presence of fever is less 
in this group 
 Most patients had acute presentation. 
 Consolidation was a predominant radiological pattern 
 Tuberculosis & bacterial infections are equally common. 
 75% of patients in whom treatment modified improved. 
 Like post-transplant group hypoxemia was frequently encountered 
complication during the procedure 
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SALIENT FEATURES OF HAEMATOLOGICAL MALIGNANCY 
GROUP 
 Chest symptoms followed by fever are most common presenting symptoms. 
 Fungal infections are more predominant in this group. 
 50% of patients, treatment was modified based on bronchoscopic results and 
all patients in whom treatment modified improved. 
 The overall complication rate is low if patients are properly worked up before 
the procedure like BT, CT, PT, a PTT, Platelet counts etc. 
SALIENT FEATURES OF CTD GROUP 
 Presence of fever at the time of initial presentation was less. This was 
probably because of the high level of immune suppression induced by drugs. 
  In radiology reticular pattern was the most common presentation & because 
of the presence of underlying pulmonary interstitial involvement due to 
primary disease process per se. 
 Diffuse pattern in radiological presentation was more common. 
 Bacterial infection followed by tuberculosis were the common infective 
aetiologies. 
 Out of 3 patients who were started on biological agents 2 developed 
tuberculosis. 
 Bronchoscopy led to change in current treatment plan in 57%, out of which 
75% improved clinically. 
 Complications were low, bronchoscopy was safe and well tolerated.  
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CONCLUSION 
 In our study, among Non-HIV immunocompromised patients with 
pulmonary diseases, we found Bronchoscopy as an useful tool. The yield 
of bronchoscopy was high (80%) despite empirical antimicrobial therapy. 
  Out of positive bronchoscopic yield, 65% were due to infectious cause and 
15% had non-infectious etiology. If bronchoscopy had not been performed, 
non-infectious cause could have been easily missed and treated as 
infectious.   
 Among the infectious causes bacterial infections were the predominant 
cause of pulmonary disease (35% overall). Gram negative bacteria 
followed by MRSA were most common among the bacterial infections. 
 Since Tuberculosis was second most common infectious cause (24% 
overall) it has to be ruled out in all non-HIV immunocompromised patients 
with pulmonary diseases in high prevalence countries.  
  CBNAAT led to increased detection of tuberculous infection in our study 
when compared to BAL AFB staining. Hence genotypic test should be 
offered to all non-HIV immunocompromised for diagnosis of tuberculosis.  
 Even though fungal infections were common among immunocompromised 
(23 % overall), we could attribute only 2/3rd as proven or probable fungal 
infections and remaining 1/3rd were colonizers. 
 Presence of fever, alveolar & a focal pattern of infiltrates, upper lobe 
involvement increased the infectious yield of bronchoscopy. 
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 Overall bacterial infections were more common among renal transplant 
group, fungal infections among hematological malignancy group and 
tuberculosis was more common connective tissue group followed by CKD 
group.  
 Complications of bronchoscopy in our study were only minor. Proper pre-
procedure evaluation and patient selection and monitoring during the 
procedure reduced the complication rate. 
 The current empirical treatment was modified to the most appropriate 
treatment in 57% who underwent bronchoscopy. Among the treatment 
modified group, 70% improved clinically.   
 For clinically stable patients early bronchoscopy before starting empirical 
treatment can be the preferred approach. Patients who are clinically 
unstable or not fit for procedure, early empirical treatment is advised, 
followed by bronchoscopy once the general conditions improve or if the 
patient does not respond to empirical therapy.  
 In summary, bronchoscopy among Non-HIV immune compromised 
patients was a safe procedure with good diagnostic yield and therapeutic 
utility. Hence, when encountered with a non-HIV immune compromised 
patient with pulmonary disease, early bronchoscopy must be preferred, as 
the benefits outweighs the risk.  
 
 
 
  
 
LIMITATIONS 
 The sample size of the study was small, and the sample size was not 
distributed equally among all groups. 
 Methods to detect respiratory viruses and certain atypical microbes 
like Mycoplasma from BAL sample was included in the study 
methodology. 
 Since sputum AFB positive cases were excluded from the study the 
overall incidence of tuberculosis may be underestimated in Non-HIV 
immunocompromised patients. 
 Very sick patients and patients with an unstable general condition 
were excluded from the study.  
 This study was done at a specialized tertiary care hospital and hence 
may not reflect the pattern of infection among non-HIV 
immunocompromised patients at community level. So further large 
scale studies are needed among non-HIV immunocompromised 
patients. 
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ABBREVIATIONS 
 
HIV – HUMAN IMMUNODEFICIENCY VIRUS 
BMT – BONE MARROW TRANSPLANT 
SOT – SOLID ORGAN TRANSPLANT 
BAL – BRONCHO ALVEOLAR LAVAGE 
CDC – CENTER FOR DISEASE CONTROL 
IDSA – INFECTIOUS DISEASE OF AMERICA  
HSCT – HAEMATOPOIETIC STEM CELL TRANSPLANT 
CMV – CYTOMEGALO VIRUS 
RSV – RESPIRATORY SYNCYTIAL VIRUS  
CLL – CHRONIC LYMPHOCYTIC LEUKEMIA  
PCP – PNEUMOCYTIS CARINI PNEUMONIA  
MTB – MYCOBSCTERIUM TUBERCULOSIS 
DAH – DIFFUSE ALVEOLAR HAEMORRHAGE  
DAD – DIFFUSE ALVEOLAR DAMAGE  
PBS – PROTECTED BRUSH SAMPLING 
TBLB – TRANS BRONCHIAL BIOPSY 
  
 
FOB – FIBER OPTIC BRONCHOSCOPY 
GGO – GROUND GLASS OPACITY 
BT – BLEEDING TIME, CT – CLOTTING TIME  
PT – PROTHROMBIN TIME, APTT- ACTIVATED PARTIAL 
THROMBOPLASTIN TIME  
EORTC - EUROPEAN ORGANIZATION FOR RESEARCH AND 
TREATMENT OF CANCER/INVASIVE FUNGAL INFECTIONS 
COOPERATIVE GROUP 
ICD – INTER COSTAL DRAIN  
CKD – CHRONIC KIDNEY DISEASE  
CTD – CONNECTIVE TISSUE DISEASE 
MRSA – METHICILLIN RESISTANT STAPHLYOCOCCUS AUREUS  
TGB – THIOGLYCOLATE BROTH 
SDA – SABURODS DEXTROSE AGAR 
BA – BLOOD AGAR 
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